Quoc Le-nguyen

Biography

Quoc Le-Nguyen joined Aduro in September 2015 and has served as our Senior Vice President of Chemistry, Manufacturing and Control (CMC) since September 2016. He brings over 25 years of experience in biopharmaceutical operations, having held positions of increasing responsibility at both large pharmaceutical and start-up companies. Prior to joining Aduro, Mr. Le-Nguyen spent seven years at Bayer Healthcare as the Vice President of Technical Operations. Before Bayer, he served at Chiron Corporation (and Novartis AG) as Director of Manufacturing Operations. Earlier in his career, he served as Senior Manager of Manufacturing Operations at BioMarin Pharmaceutical, where he played an integral role in bringing the company’s lead drug candidate from Phase 3 to commercial launch. Mr. Le-Nguyen holds a B.S. from University of California, Davis in Biochemistry. Blaine Templeman Executive Vice President, General Counsel and Secretary Blaine Templeman joined Aduro as Executive Vice President, General Counsel and Secretary in September 2015. He brings over 20 years of experience counseling biotechnology companies in the development and commercialization of their products. Prior to joining Aduro, Mr. Templeman was a corporate and intellectual property partner at Arnold & Porter LLP, where he counseled U.S. and international clients on the protection, development and commercialization of their products, intellectual property portfolios, contract manufacturing, clinical trials, research and outsourcing. His transactional experience includes a variety of collaborations, licensing transactions, mergers and acquisitions, asset sales, manufacturing and distribution arrangements and co-promotion transactions. Before Arnold & Porter LLP, he was a partner at Heller Ehrman. Mr. Templeman holds a J.D. from New York University and a B.S. from Oral Roberts University. Sylvia Wheeler Senior Vice President, Corporate Affairs and Investor Relations Sylvia Wheeler joined Aduro as Senior Vice President, Corporate Affairs and Investor Relations in January 2015. She brings over 20 years of experience in the biopharmaceutical industry, having served in a number of executive management roles encompassing investor and media relations, as well as corporate and product communications. Prior to joining Aduro, Ms. Wheeler served as Vice President of Investor Relations and Corporate Affairs at Relypsa after having served this same role for Hyperion Therapeutics. Earlier in her career, she was Vice President, Corporate Communications at Affymax where, over a six-year-period, she supported the company’s transition from a research and development company to a commercial organization with its first marketed product. Ms. Wheeler held similar communications roles at Depomed, Cerus Corporation and Coulter Pharmaceutical. Ms. Wheeler holds an M.B.A. from University of San Francisco and a B.A. in Biology from San Francisco State University. Michele DeVries Vice President, Regulatory Affairs Michele DeVries joined Aduro in 2013 and currently serves as Vice President of Regulatory Affairs. She is responsible for all aspects of regulatory strategy, implementation and oversight of Aduro’s proprietary, partnered and licensed programs, both in the U.S. and internationally. Prior to Aduro, Ms. DeVries served as Director of Regulatory Affairs for Intarcia Therapeutics. In this role she managed key regulatory aspects of Intarcia’s drug delivery system, served as the primary contact for regulatory authorities, and was responsible for all aspects of routine and specialized regulatory submissions, including preparation for launch of four global Phase 3 studies. Before Intarcia, she held escalating regulatory affairs positions at VaxGen, InterMune and Tularik. She received her B.S. in Chemical Engineering from the University of Minnesota. Celeste Ferber Vice President, Associate General Counsel Celeste Ferber joined Aduro in 2016 and currently serves as Vice President, Associate General Counsel. Prior to Aduro, she was with Shearman & Sterling LLP, where she served as counsel in the capital markets group. Ms. Ferber has over 15 years of experience advising public and private companies on corporate and finance matters, including securities offerings, mergers, acquisitions and strategic transactions, corporate governance and securities law compliance. Before Shearman & Sterling, Ms. Ferber was counsel at Morrison & Foerster LLP working in their Palo Alto, Hong Kong and San Diego offices. Ms. Ferber received her J.D. from the University of California, Hastings College of Law and her B.A. in Economics from Bucknell University. She is the author of numerous publications regarding legal matters. Nancy Kaplan Vice President, Human Resources and Facility Operations Nancy Kaplan joined Aduro in 2008 and currently serves as Aduro’s Vice President of Human Resources and Facility Operations. Prior to Aduro, Ms. Kaplan worked with a wide variety of small biotech companies, applying her broad generalist skill set to establish and bolster finance, human resources, facility management, grant administration and investor relations functions. In addition, she was Marketing Communications Manager at Applied Biosystems and supervised biotech accounts at Lena Chow Advertising. Earlier in her career, Ms. Kaplan was part of the founding group at Invitron Corp, a mammalian cell contract manufacturer. Ms. Kaplan holds a B.S. in Agronomy from Oregon State University. Anne Moon, Ph.D. Vice President, Project Management Anne Moon, Ph.D., joined Aduro in 2014 and currently serves as Vice President of Project Management. Prior to Aduro, Dr. Moon was a founding team member of Jennerex Biotherapeutics (acquired by SillaJen), where she served as Vice President of Product Development. Earlier in her career, Dr. Moon was part of the start-up team at Cytokinetics, establishing the cell-based screening program and served as Project Manager of the oncolytic virus program at Onyx Pharmaceuticals (acquired by Amgen) after completing postdoctoral work within the small molecule therapeutics program targeting small GTPases. She received her Ph.D. in Molecular and Cell Biology from the University of California, Berkeley, and her B.A. in Biology from Harvard University. Aimee Murphy Vice President, Clinical Development and Operations Ms. Murphy joined Aduro in 2009 and currently serves as Vice President of Clinical Development and Operations. Prior to Aduro, Ms. Murphy advanced the development of the LADD (live, attenuated double-deleted) immunotherapy platform at both Cerus Corporation and Anza Therapeutics, where she managed the first Phase 1 studies that led to Aduro's existing LADD clinical programs. Prior to focusing on LADD, she worked on the development of prophylactic vaccines and drugs for oncology and infectious diseases at VaxGen, Coulter Pharmaceuticals, and Shaman Pharmaceuticals. Additionally, Ms. Murphy brings experience in quality assurance from Bayer Pharmaceuticals. She holds a B.S. in Biology from Pepperdine University. Justin Skoble, Ph.D. Vice President, Technical Operations Justin Skoble, Ph.D., joined Aduro in 2009 and currently serves as Aduro’s Vice President of Technical Operations. Prior to Aduro, Dr. Skoble held positions with increasing responsibilities in the molecular biology and process development departments at Anza Therapeutics and Cerus Corporation. He earned his B.A. in Biology from Vassar College and his Ph.D. in Molecular and Cell Biology from the University of California, Berkeley, in the laboratory of Dr. Daniel Portnoy. Additionally, Dr. Skoble performed postdoctoral work at the University of California, San Francisco (UCSF), in the laboratory of Dr. Jeff Cox, Professor of Microbiology and Immunology at UCSF. Liana Wu Vice President, Commercial Liana Wu joined Aduro in April 2015 as Vice President, Commercial, bringing with her over 17 years of commercial experience in the biotechnology industry and a successful track record in brand development and product launches. Prior to Aduro, Ms. Wu spent nine years at Onyx Pharmaceuticals (acquired by Amgen) where she was most recently Vice President, Oncology Franchise. While at Onyx, she was instrumental in overseeing the collaboration with Bayer for Nexavar and Stivarga in the United States. Earlier in her career, Ms. Wu held several sales and marketing positions at Genentech, with responsibilities associated with the company’s key oncology brands, including Rituxan, Herceptin, and Tarceva. Ms. Wu holds a Master’s in Public Health from The Johns Hopkins University and a B.S. in Economics from the Wharton School at the University of Pennsylvania.  

Research Interest

 biopharmaceutical operations